Popular Trials
Monoclonal Antibodies
MK-7684A for Advanced Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment that combines two medications to see if it works better than the current treatment for serious cancers, particularly cervical cancer. One of the medications has shown promising results in treating various cancers, including cervical cancer. The goal is to find out if this combination can improve patient outcomes by helping the immune system fight cancer more effectively.
Anti-tumor antibiotic
Nab-Paclitaxel + Paclitaxel + Ramucirumab for Stomach Cancer
Recruiting1 awardPhase 1
Duarte, California
"This trial is testing a new way of delivering chemotherapy directly into the abdominal cavity using a mist (aerosolized) form of nab-paclitaxel. The study will also combine this new
Procedure
Endoscopy for Stomach Cancer Detection and Prevention
Recruiting1 award
New Brunswick, New Jersey
This trial provides three distinct opportunities to decrease gastric cancer (GC) morbidity and mortality. It has potential to discover cancer in early stages before the onset of symptoms, leading to higher rates of survival. Second, premalignant lesions such as adenomatous polyps, intestinal metaplasia and dysplasia can be discovered and removed with local resection, akin to polypectomies during screening colonoscopies, preventing the development of cancer. Third, EGD discovery and treatment of active Helicobacter pylori (HP) infection of the stomach provides an opportunity for primary prevention of GC.
Chemotherapy
ASP2138 for Digestive System Cancers
Recruiting1 awardPhase 1
Dallas, Texas
This trial is testing a new drug called ASP2138 for adults with advanced stomach, gastroesophageal junction, or pancreatic cancer. ASP2138 helps the immune system target and attack cancer cells. The study aims to find a safe and effective dose and monitor any side effects. Participants will receive the drug through an IV or injection and will be closely monitored throughout the study.
Popular Filters
Trials for Adenocarcinoma Patients
Monoclonal Antibodies
SGN-CEACAM5C for Advanced Cancers
Recruiting1 awardPhase 1
Grand Rapids, Michigan
This trial is testing a new drug called SGN-CEACAM5C for patients with hard-to-treat solid tumors that have either returned or didn't respond to standard treatments. The drug targets cancer cells and kills them. The study will determine the safe dosage and effectiveness of the drug.
Cancer Vaccine
EO-3021 for Gastrointestinal Cancer
Recruiting1 awardPhase 1
Nashville, Tennessee
This trial is testing a new treatment for adult patients with solid tumors that have a specific marker called CLDN18.2. The treatment aims to find and destroy cancer cells with this marker. This approach helps target the cancer more precisely without affecting normal cells. CLDN18.2 has been identified as a promising target for cancer therapy, particularly in gastric cancer.
CAR T-cell Therapy
TCR-T Cell Therapy for Cancer
Recruiting1 awardPhase 1
New Brunswick, New Jersey
This trial tests a new treatment using modified immune cells to target specific cancers. It focuses on patients with certain metastatic cancers that produce an abnormal protein. The treatment aims to use the body's own enhanced immune system to fight cancer.
Telehealth Diet Management for Stomach Cancer Post-Surgery
Recruiting1 award
Duarte, California
This trial will see if a diet intervention can help with nutrition and quality of life after surgery for esophagus or stomach cancer. The study could help patients get more information and support on eating after surgery.
Monoclonal Antibodies
SGN-B6A for Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Trials for Gastric Adenocarcinoma Patients
Monoclonal Antibodies
SGN-CEACAM5C for Advanced Cancers
Recruiting1 awardPhase 1
Grand Rapids, Michigan
This trial is testing a new drug called SGN-CEACAM5C for patients with hard-to-treat solid tumors that have either returned or didn't respond to standard treatments. The drug targets cancer cells and kills them. The study will determine the safe dosage and effectiveness of the drug.
CAR T-cell Therapy
TCR-T Cell Therapy for Cancer
Recruiting1 awardPhase 1
New Brunswick, New Jersey
This trial tests a new treatment using modified immune cells to target specific cancers. It focuses on patients with certain metastatic cancers that produce an abnormal protein. The treatment aims to use the body's own enhanced immune system to fight cancer.
Telehealth Diet Management for Stomach Cancer Post-Surgery
Recruiting1 award
Duarte, California
This trial will see if a diet intervention can help with nutrition and quality of life after surgery for esophagus or stomach cancer. The study could help patients get more information and support on eating after surgery.
Monoclonal Antibodies
SGN-B6A for Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Platinum Coordination Complex
mFOLFIRINOX for Stomach Cancer
Recruiting3 awardsPhase 4
Chicago, Illinois
This trial is studying how well a combination of modified fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin works in treating patients with gastroesophageal or stomach cancer.
Phase 3 Trials
Anti-metabolites
Chemotherapy for Pancreatic Cancer
Recruiting2 awardsPhase 3
Mobile, Alabama
This trial is studying gemcitabine hydrochloride given with or without erlotinib hydrochloride, followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil, to see how well it works in treating patients with pancreatic cancer that has been removed by surgery.
Alkylating agents
Chemotherapy +/− Bevacizumab for Ovarian Cancer
Recruiting2 awardsPhase 3
Anchorage, Alaska
This trial is studying carboplatin, paclitaxel, and gemcitabine hydrochloride given together with or without bevacizumab after surgery to treat patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer.
Radiation Therapy
Intense Radiotherapy for Prostate Cancer
Recruiting2 awardsPhase 3
Saint John, New Brunswick
This trial is designed to determine whether high risk prostate cancer patients can be safely treated with a shorter, more intense radiation therapy regimen. 3D-Conformal Radiotherapy (3D-CRT) or Intensity Modulated Radiotherapy (IMRT) will be used to deliver the required radiation dose. Patients will also receive 28 months of androgen deprivation therapy (LHRH agonist). The primary outcome of the study is the acute and delayed toxicity and the secondary outcomes include biochemical failure, prostate specific mortality rate, bone metastases free survival, the prognostic and predictive value of several biological variables. It is planned to recruit 250
Alkylating agents
Glufosfamide vs Fluorouracil for Pancreatic Cancer
Recruiting3 awardsPhase 3
Corona, California
This trial is testing if the chemotherapy drug glufosfamide can help people with advanced pancreatic cancer live longer. These patients have already tried another treatment called gemcitabine, which didn't work for them. Glufosfamide aims to stop cancer cells from growing by damaging their DNA.
Trials With No Placebo
Monoclonal Antibodies
SGN-CEACAM5C for Advanced Cancers
Recruiting1 awardPhase 1
Grand Rapids, Michigan
This trial is testing a new drug called SGN-CEACAM5C for patients with hard-to-treat solid tumors that have either returned or didn't respond to standard treatments. The drug targets cancer cells and kills them. The study will determine the safe dosage and effectiveness of the drug.
Cancer Vaccine
EO-3021 for Gastrointestinal Cancer
Recruiting1 awardPhase 1
Nashville, Tennessee
This trial is testing a new treatment for adult patients with solid tumors that have a specific marker called CLDN18.2. The treatment aims to find and destroy cancer cells with this marker. This approach helps target the cancer more precisely without affecting normal cells. CLDN18.2 has been identified as a promising target for cancer therapy, particularly in gastric cancer.
CAR T-cell Therapy
TCR-T Cell Therapy for Cancer
Recruiting1 awardPhase 1
New Brunswick, New Jersey
This trial tests a new treatment using modified immune cells to target specific cancers. It focuses on patients with certain metastatic cancers that produce an abnormal protein. The treatment aims to use the body's own enhanced immune system to fight cancer.
Telehealth Diet Management for Stomach Cancer Post-Surgery
Recruiting1 award
Duarte, California
This trial will see if a diet intervention can help with nutrition and quality of life after surgery for esophagus or stomach cancer. The study could help patients get more information and support on eating after surgery.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.